Drug Pipeline

CD19 CAR-T cells Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
4
Recruiting
3
Top Sponsors
Active Studies by Phase
Phase 2
1
Phase 1/2
2
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT04661020 CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma Large B-Cell Lymphoma (LBCL) Recruiting
Phase 1/2
NCT06585514 Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus Systemic Lupus Erythematosus (SLE) Recruiting
NCT06688799 Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases Autoimmune Diseases Recruiting
Phase 1
NCT07331467 Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE Systemic Lupus Erythematosus Recruiting
Sponsors Running CD19 CAR-T cells Trials
Beijing GoBroad Hospital (2) Zhejiang University (1) Chongqing Precision Biotech Co., Ltd (1)
Disease Areas
Lupus (SLE) (2)
Get alerts when CD19 CAR-T cells trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free